Details of the Drug
General Information of Drug (ID: DM84YCI)
| Drug Name |
12-(3-Adamantan-1-yl-ureido)-dodeca noic acid
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
AUDA; 479413-70-2; CHEMBL215387; Urea-based compound, 18; 12-[(adamantan-1-ylcarbamoyl)amino]dodecanoic acid; MLS002415562; SCHEMBL120588; CTK8F0781; BDBM25737; DTXSID20435153; HMS3650M09; HMS2204E15; HMS3332K06; AUDA, > ZINC27645646; MFCD12912267; 1631AH; SMR001339077; ACM479413702; RT-011342; 12-(3-adamantan-1-yl-ureido)-dodecanoic acid; SR-01000860315; SR-01000860315-2; 12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 392.6 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 5.9 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 13 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||


